# US 2021/0332193 A1 · Amino acid-modified polymer for adhesion prevention and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332193 A1
- Document ID: US20210332193A1
- Status: Published application
- Kind: A1
- Application number: 17/239,133
- Filed: 2021-04-23
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: Pro-View Biotech Co., Ltd.
- Applicants: Pro-View Biotech Co., Ltd.
- Inventors: Yu-Chia CHANG; Yunn-Kuen CHANG; Wen-Yen HUANG; Ging-Ho HSIUE; Hsieh-Chih TSAI; Shuian-Yin LIN; Nai-Sheng HSU; Tzu-Yu LIN
- Web page: https://patentgrep.com/patent/US20210332193A1

## CPC

- C08G 65/33306: {acyclic}
- C08G 81/00: Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42})
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 31/041: {Mixtures of macromolecular compounds}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- C08G 65/3344: {containing oxygen in addition to sulfur}
- C08L 71/02: Polyalkylene oxides
- A61L 2300/216: with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/424: Anti-adhesion agents
- C08G 2650/58: Ethylene oxide or propylene oxide copolymers, e.g. pluronics
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Synthetic amino acid-modified polymers and methods of making the same and using the same are disclosed. The synthetic amino acid-modified polymers possess distinct thermosensitive, improved water-erosion resistant, and enhanced mechanical properties, and are suitable of reducing or preventing formation of postoperative tissue adhesions. Additionally, the amino acid-modified polymers can also be used as a vector to deliver pharmaceutically active agents.

## Claims

### Claim 1

A polymer having a structure of the following formula (I):
wherein:
POLY is a triblock copolymer of poly(ethylene oxide)(PEO)-poly(propylene oxide)(PPO)-poly(ethylene oxide)(PEO);
m and n are independently from each other 0 or 1, wherein m and n cannot be 0 simultaneously; and
AA is an amino acid residue, where its amino group directly binds to the chain-end of the POLY to form carbamate (O—C(═O)—NH) linkage.

### Claim 2 (depends on 1)

The polymer of claim 1, wherein POLY has an average molecular weight ranging from 1,000 to 20,000 Daltons.

### Claim 3 (depends on 1)

The polymer of claim 1, wherein POLY is selected from the group consisting of Pluronic F-127 (PF127), Pluronic F-68 (PF68), and Pluronic L-35 (PL35).

### Claim 4 (depends on 1)

The polymer of claim 1, wherein the amino acid residue is selected from the group consisting of hydrophobic amino acids, basic amino acids, acidic amino acids, aromatic amino acids, and hydrophilic amino acids.

### Claim 5 (depends on 4)

The polymer of claim 4, wherein, the hydrophobic amino acid is selected from the group consisting of Glycine, Alanine, Valine, Methionine, Leucine, Isoleucine, and Phenylalanine; the basic amino acid is selected from the group consisting of Lysine, Histidine, and Arginine; the acidic amino acids is selected from the group consisting of Aspartic acid, Asparagine, and Glutamine acid; the aromatic amino acid is selected from the group consisting of Tyrosine and Tryptophan; and the hydrophilic amino acid is selected from the group consisting of Serine, Cysteine, Threonine, and Proline.

### Claim 6 (depends on 1)

The polymer of claim 1, wherein POLY is a Pluronic, and AA is selected from the group consisting of Leucine, Methionine, Lysine, Aspartic acid, Asparagine, Tyrosine, Serine, and Cysteine.

### Claim 7 (depends on 1)

The polymer of claim 1, which is used for postoperative tissue adhesion prevention and drug delivery.

### Claim 8

A composition comprising any one of polymer having a structure of the following formula (I):
or a combination thereof, and a pharmaceutically acceptable carrier;
wherein:
POLY is a triblock copolymer of poly(ethylene oxide)(PEO)-poly(propylene oxide)(PPO)-poly(ethylene oxide)(PEO);
m and n are independently from each other 0 or 1, wherein m and n cannot be 0 simultaneously; and
AA is an amino acid residue, where its amino group directly binds to the chain-end of the POLY to form carbamate (O—C(═O)—NH) linkage.

### Claim 9 (depends on 8)

The composition of claim 8, wherein POLY has an average molecular weight ranging from 1,000 to 20,000 Daltons.

### Claim 10 (depends on 8)

The composition of claim 8, wherein any one of the polymer or combinations thereof is in an amount of 5% to 30% by weight of the composition.

### Claim 11 (depends on 8)

The composition of claim 8, wherein POLY is selected from the group consisting of Pluronic F-127 (PF127), Pluronic F-68 (PF68) and Pluronic L-35 (PL35).

### Claim 12 (depends on 8)

The composition of claim 8, wherein the amino acid residue is selected from the groups consisting of hydrophobic amino acids, hydrophilic amino acids, basic amino acids, acidic amino acids, and aromatic amino acids.

### Claim 13 (depends on 12)

The composition of claim 12, the hydrophobic amino acid is selected from the group consisting of Glycine, Alanine, Valine, Methionine, Leucine, Isoleucine, and Phenylalanine; the basic amino acid is selected from the group consisting of Lysine, Histidine, and Arginine; the acidic amino acids is selected from the group consisting of Aspartic acid, Asparagine, and Glutamine acid; the aromatic amino acid is selected from the group consisting of Tyrosine and Tryptophan; and the hydrophilic amino acid is selected from the group consisting of Serine, Cysteine, Threonine, and Proline.

### Claim 14 (depends on 8)

The composition of claim 8, wherein POLY is a Pluronic, and AA is selected from the group consisting of Leucine, Methionine, Lysine, Aspartic acid, Asparagine, Tyrosine, Serine, and Cysteine.

### Claim 15 (depends on 8)

The composition of claim 8, wherein the combination is two or more of formula (I) mixed, wherein POLY is a Pluronic F-127 (PF127), and AA is selected from the group consisting of Lysine, Serine, and Cysteine.

### Claim 16 (depends on 8)

The composition of claim 8, further comprising a pharmaceutically active agent.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the pharmaceutically active agent is selected from the group consisting of anticancer drugs, antibiotics, hemostatic agents, steroids, non-steroidal anti-inflammatory drugs, hormones, analgesics, and anesthetics.

### Claim 18 (depends on 8)

Use of the composition of claim 8 for the prevention of postoperative tissue adhesion and drug delivery.
